Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
Background: The aim of this research is to study the influence of simultaneous taking of tadalafil and solifenacin in standard and double dosage on the lower urinary tract symptoms (LUTS) and sexual dysfunction in men with benign prostatic hyperplasia after the course of dutasteride. Materials and m...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Prostate International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888220300076 |
id |
doaj-37757c324ee54c578bc427f59a7fca5f |
---|---|
record_format |
Article |
spelling |
doaj-37757c324ee54c578bc427f59a7fca5f2020-11-25T03:52:08ZengElsevierProstate International2287-88822020-06-01827884Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasterideKirill V. Kosilov0Irina G. Kuzina1Vladimir Kuznetsov2Ekaterina K. Kosilova3Department of Social Sciences, School of Humanities, Far Eastern Federal University, Vladivostok, Primorsky Region, Russian Federation; Corresponding author. RUVVO, Ayax 10, F733, DVFU, Vladivostok, Russian Federation.Department of Social Science, Far Eastern Federal University, Vladivostok, Primorsky Region, Russian FederationDepartment of Public Health, Pacific State Medical University, Vladivostok, Primorsky Region, Russian FederationPacific State Medical University, Vladivostok, Primorsky Region, Russian FederationBackground: The aim of this research is to study the influence of simultaneous taking of tadalafil and solifenacin in standard and double dosage on the lower urinary tract symptoms (LUTS) and sexual dysfunction in men with benign prostatic hyperplasia after the course of dutasteride. Materials and methods: The research included 326 patients older than 50 years with benign prostatic hyperplasia coupled with LUTS and sexual dysfunction having undergone the course of treatment with dutasteride. After random division into three groups, patients from the Group A (n = 107) got tadalafil 5 mg/d as monotherapy, from the Group В (n = 107) got tadalafil 5 mg/d and solifenacin 10 mg/d, and from the Group С (n = 112) got tadalafil 5 mg/d and solifenacin 20 mg/d. The duration of treatment was 12 weeks. The rating of sexual function was made with the questionnaires International Index of Erectile Function and other. Results: The results of rating of sexual function with the questionnaires MSHQ-EjD and International Index of Erectile Function correlated among themselves. According to MSHQ-EjD, overall rating of the sexual function increased in each of the three groups (A: 67.9 (12.4)/91.5 (10.4), P ≤ 0.05; B: 72.4 (14.5)/102.6 (16.9), P ≤ 0.05; C: 76.6 (16.3)/109.6 (15.6), P ≤ 0.05). The level of hyperactivity symptoms decreased in Groups В and С (В: urgency −2.9 (0.7)/1.1 (0.6), P ≤ 0.05; nocturia 2.7 (1.0)/0.7 (0.5), P ≤ 0.05; C: urgency −2.5 (0.5)/0.8 (0.6), P ≤ 0.05; nocturia −2.8 (0.6)/1.0 (0.5), P ≤ 0.05), and it did not change in the Group A. Conclusions: The use of tadalafil as monotherapy significantly improves the sexual function but does not affect overactive bladder symptoms. The combination therapy of tadalafil and solifenacin leads to dramatic improvement of sexual function and reversibility of detrusor hyperactivity symptoms.http://www.sciencedirect.com/science/article/pii/S2287888220300076Benign prostatic hyperplasiaDutasterideLower urinary tract symptomsSexual dysfunctionSolifenacinTadalafil |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kirill V. Kosilov Irina G. Kuzina Vladimir Kuznetsov Ekaterina K. Kosilova |
spellingShingle |
Kirill V. Kosilov Irina G. Kuzina Vladimir Kuznetsov Ekaterina K. Kosilova Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride Prostate International Benign prostatic hyperplasia Dutasteride Lower urinary tract symptoms Sexual dysfunction Solifenacin Tadalafil |
author_facet |
Kirill V. Kosilov Irina G. Kuzina Vladimir Kuznetsov Ekaterina K. Kosilova |
author_sort |
Kirill V. Kosilov |
title |
Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride |
title_short |
Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride |
title_full |
Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride |
title_fullStr |
Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride |
title_full_unstemmed |
Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride |
title_sort |
improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride |
publisher |
Elsevier |
series |
Prostate International |
issn |
2287-8882 |
publishDate |
2020-06-01 |
description |
Background: The aim of this research is to study the influence of simultaneous taking of tadalafil and solifenacin in standard and double dosage on the lower urinary tract symptoms (LUTS) and sexual dysfunction in men with benign prostatic hyperplasia after the course of dutasteride. Materials and methods: The research included 326 patients older than 50 years with benign prostatic hyperplasia coupled with LUTS and sexual dysfunction having undergone the course of treatment with dutasteride. After random division into three groups, patients from the Group A (n = 107) got tadalafil 5 mg/d as monotherapy, from the Group В (n = 107) got tadalafil 5 mg/d and solifenacin 10 mg/d, and from the Group С (n = 112) got tadalafil 5 mg/d and solifenacin 20 mg/d. The duration of treatment was 12 weeks. The rating of sexual function was made with the questionnaires International Index of Erectile Function and other. Results: The results of rating of sexual function with the questionnaires MSHQ-EjD and International Index of Erectile Function correlated among themselves. According to MSHQ-EjD, overall rating of the sexual function increased in each of the three groups (A: 67.9 (12.4)/91.5 (10.4), P ≤ 0.05; B: 72.4 (14.5)/102.6 (16.9), P ≤ 0.05; C: 76.6 (16.3)/109.6 (15.6), P ≤ 0.05). The level of hyperactivity symptoms decreased in Groups В and С (В: urgency −2.9 (0.7)/1.1 (0.6), P ≤ 0.05; nocturia 2.7 (1.0)/0.7 (0.5), P ≤ 0.05; C: urgency −2.5 (0.5)/0.8 (0.6), P ≤ 0.05; nocturia −2.8 (0.6)/1.0 (0.5), P ≤ 0.05), and it did not change in the Group A. Conclusions: The use of tadalafil as monotherapy significantly improves the sexual function but does not affect overactive bladder symptoms. The combination therapy of tadalafil and solifenacin leads to dramatic improvement of sexual function and reversibility of detrusor hyperactivity symptoms. |
topic |
Benign prostatic hyperplasia Dutasteride Lower urinary tract symptoms Sexual dysfunction Solifenacin Tadalafil |
url |
http://www.sciencedirect.com/science/article/pii/S2287888220300076 |
work_keys_str_mv |
AT kirillvkosilov improvementofthesymptomsoflowerurinarytractandsexualdysfunctionwithtadalafilandsolifenacinafterthetreatmentofbenignprostatichyperplasiawithdutasteride AT irinagkuzina improvementofthesymptomsoflowerurinarytractandsexualdysfunctionwithtadalafilandsolifenacinafterthetreatmentofbenignprostatichyperplasiawithdutasteride AT vladimirkuznetsov improvementofthesymptomsoflowerurinarytractandsexualdysfunctionwithtadalafilandsolifenacinafterthetreatmentofbenignprostatichyperplasiawithdutasteride AT ekaterinakkosilova improvementofthesymptomsoflowerurinarytractandsexualdysfunctionwithtadalafilandsolifenacinafterthetreatmentofbenignprostatichyperplasiawithdutasteride |
_version_ |
1724484059684405248 |